Fuminori Moriyasu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fuminori Moriyasu has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Takao Itoi
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan
31 shared publications - Atsushi Sofuni
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan
24 shared publications - Takayoshi Tsuchiya
Department of Gastroenterology and Hepatology Tokyo Medical University Tokyo Japan
19 shared publications - Fumihide Itokawa
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan
18 shared publications - Toshio Kurihara
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan
17 shared publications Nobuhito Ikeuchi
16 shared publications
Latest Publications
- Open Access
- 4 April 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (4) , 767
Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination
This study evaluated the clinical use of serum metabolomics to discriminate malignant cancers including pancreatic cancer (PC) from malignant diseases, such as biliary tract cancer (BTC), intraductal papillary mucinous carcinoma (IPMC), and various benign pancreaticobiliary diseases. Capillary electrophoresismass spectrometry was used to analyze charged metabolites. We repeatedly analyzed serum samples (n = 41) of different storage durations to identify metabolites showing high quantitative reproducibility, and subsequently analyzed all samples (n = 140). Overall, 189 metabolites were quantified and 66 metabolites had a 20% coefficient of variation and, of these, 24 metabolites showed significant differences among control, benign, and malignant groups (p < 0.05; Steel–Dwass test). Four multiple logistic regression models (MLR) were developed and one MLR model clearly discriminated all disease patients from healthy controls with an area under receiver operating characteristic curve (AUC) of 0.970 (95% confidential interval (CI), 0.946–0.994, p < 0.0001). Another model to discriminate PC from BTC and IPMC yielded AUC = 0.831 (95% CI, 0.650–1.01, p = 0.0020) with higher accuracy compared with tumor markers including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), pancreatic cancer-associated antigen (DUPAN2) and s-pancreas-1 antigen (SPAN1). Changes in metabolomic profiles might be used to screen for malignant cancers as well as to differentiate between PC and other malignant diseases.
- 4 April 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (4) , 767
Open AccessSerum Metabolomic Profiles for Human Pancreatic Cancer Discrimination
This study evaluated the clinical use of serum metabolomics to discriminate malignant cancers including pancreatic cancer (PC) from malignant diseases, such as biliary tract cancer (BTC), intraductal papillary mucinous carcinoma (IPMC), and various benign pancreaticobiliary diseases. Capillary electrophoresismass spectrometry was used to analyze charged metabolites. We repeatedly analyzed serum samples (n = 41) of different storage durations to identify metabolites showing high quantitative reproducibility, and subsequently analyzed all samples (n = 140). Overall, 189 metabolites were quantified and 66 metabolites had a 20% coefficient of variation and, of these, 24 metabolites showed significant differences among control, benign, and malignant groups (p < 0.05; Steel–Dwass test). Four multiple logistic regression models (MLR) were developed and one MLR model clearly discriminated all disease patients from healthy controls with an area under receiver operating characteristic curve (AUC) of 0.970 (95% confidential interval (CI), 0.946–0.994, p < 0.0001). Another model to discriminate PC from BTC and IPMC yielded AUC = 0.831 (95% CI, 0.650–1.01, p = 0.0020) with higher accuracy compared with tumor markers including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), pancreatic cancer-associated antigen (DUPAN2) and s-pancreas-1 antigen (SPAN1). Changes in metabolomic profiles might be used to screen for malignant cancers as well as to differentiate between PC and other malignant diseases.
- 8 August 2016
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 52 (5) , 568-576
Dual red imaging (novel advanced endoscopy) can increase visibility and can predict the depth in diagnosing esophageal varices
- 8 August 2016
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 52 (5) , 568-576
Dual red imaging (novel advanced endoscopy) can increase visibility and can predict the depth in diagnosing esophageal varices
- Open Access
- 17 June 2016
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 749
Optimal injection rate of ultrasound contrast agent for evaluation of focal liver lesions using an automatic power injector: a pilot study
To determine the optimal bolus injection rate of ultrasound (US) contrast agent in vascular imaging for focal liver lesions. Thirteen patients with 13 focal liver lesions (5 hepatocellular carcinomas (HCCs) with cirrhosis, 4 liver metastases, 2 hemangiomas, 1 intrahepatic cholangiocarcinoma, 1 focal nodular hyperplasia) received two bolus injections of Sonazoid (at 0.5 and 2.0 mL/s) using an automatic power injector. The lesion-to-liver contrast ratio at peak enhancement was quantitatively evaluated. Enhancement of the lesions compared to liver parenchyma was assessed by two independent readers using a five-point scale and qualitatively evaluated by receiver operating characteristic (ROC) analysis. For all lesions, the contrast ratio was not significantly different between the two injection rates. For HCCs, the contrast ratio was higher at 0.5 mL/s (7.41 ± 6.56) than at 2.0 mL/s (4.28 ± 4.66, p = 0.025). For all lesions, the mean area under the ROC curve (AUC) was not significantly different between the two injection rates. For HCCs, the AUC was greater at 0.5 mL/s than at 2.0 mL/s (AUC: 0.86, p = 0.013). In contrast-enhanced US, an injection rate of 0.5 mL/s is superior to an injection rate of 2.0 mL/s for the quantitative and qualitative analysis of HCCs in the cirrhotic liver.
- 17 June 2016
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 749
Open AccessOptimal injection rate of ultrasound contrast agent for evaluation of focal liver lesions using an automatic power injector: a pilot study
To determine the optimal bolus injection rate of ultrasound (US) contrast agent in vascular imaging for focal liver lesions. Thirteen patients with 13 focal liver lesions (5 hepatocellular carcinomas (HCCs) with cirrhosis, 4 liver metastases, 2 hemangiomas, 1 intrahepatic cholangiocarcinoma, 1 focal nodular hyperplasia) received two bolus injections of Sonazoid (at 0.5 and 2.0 mL/s) using an automatic power injector. The lesion-to-liver contrast ratio at peak enhancement was quantitatively evaluated. Enhancement of the lesions compared to liver parenchyma was assessed by two independent readers using a five-point scale and qualitatively evaluated by receiver operating characteristic (ROC) analysis. For all lesions, the contrast ratio was not significantly different between the two injection rates. For HCCs, the contrast ratio was higher at 0.5 mL/s (7.41 ± 6.56) than at 2.0 mL/s (4.28 ± 4.66, p = 0.025). For all lesions, the mean area under the ROC curve (AUC) was not significantly different between the two injection rates. For HCCs, the AUC was greater at 0.5 mL/s than at 2.0 mL/s (AUC: 0.86, p = 0.013). In contrast-enhanced US, an injection rate of 0.5 mL/s is superior to an injection rate of 2.0 mL/s for the quantitative and qualitative analysis of HCCs in the cirrhotic liver.
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S323
Sa1466 Usefulness of High-Intensity Focused Ultrasound (HIFU) Therapy for Unresectable Pancreatic Cancer
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S323
Sa1466 Usefulness of High-Intensity Focused Ultrasound (HIFU) Therapy for Unresectable Pancreatic Cancer
- Open Access
- 29 January 2016
- Published by Springer Nature in Cancer Imaging
- Vol. 16 (1) , 1
Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study
Background: To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM). Methods: Nine patients were evaluated prospectively. All patients were Child-Pugh score A. The mean dimension of the lesion was 32 mm (range: 15–74 mm). MR images were obtained using a 1.5-Tesla superconductive MRI system. Diffusion-weighted imaging was performed under breath-holding using b-values of 0, 50, 100, 150, 200, 400, and 800 s/mm2. The following IVIM parameters were calculated: apparent diffusion coefficient, true diffusion coefficient (DC), pseudo-diffusion coefficient, and perfusion fraction. MRI was performed before treatment and at 1, 2, and 4 weeks after beginning treatment. Tumor response at 4 weeks was assessed by CT or MRI using modified RECIST. IVIM parameters of the treatment responders and non-responders were compared. Results: The DC of responders at baseline was significantly higher than that of the non-responders. The sensitivity and specificity, when a DC of 0.8 (10−3 mm2/s) or higher was considered to be a responder, were 100 % and 67 %, respectively. No significant differences were found in the other parameters between the responders and the non-responders. All IVIM parameters of the responders and non-responders did not change significantly after treatment. Conclusion: The DC before treatment may be a useful parameter for predicting the therapeutic outcome of sorafenib for advanced HCC.
- 29 January 2016
- Published by Springer Nature in Cancer Imaging
- Vol. 16 (1) , 1
Open AccessIntravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study
Background: To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM). Methods: Nine patients were evaluated prospectively. All patients were Child-Pugh score A. The mean dimension of the lesion was 32 mm (range: 15–74 mm). MR images were obtained using a 1.5-Tesla superconductive MRI system. Diffusion-weighted imaging was performed under breath-holding using b-values of 0, 50, 100, 150, 200, 400, and 800 s/mm2. The following IVIM parameters were calculated: apparent diffusion coefficient, true diffusion coefficient (DC), pseudo-diffusion coefficient, and perfusion fraction. MRI was performed before treatment and at 1, 2, and 4 weeks after beginning treatment. Tumor response at 4 weeks was assessed by CT or MRI using modified RECIST. IVIM parameters of the treatment responders and non-responders were compared. Results: The DC of responders at baseline was significantly higher than that of the non-responders. The sensitivity and specificity, when a DC of 0.8 (10−3 mm2/s) or higher was considered to be a responder, were 100 % and 67 %, respectively. No significant differences were found in the other parameters between the responders and the non-responders. All IVIM parameters of the responders and non-responders did not change significantly after treatment. Conclusion: The DC before treatment may be a useful parameter for predicting the therapeutic outcome of sorafenib for advanced HCC.
- 1 January 2016
- Published by Japan Gastrointestinal Endoscopy Society in Progress of Digestive Endoscopy
- Vol. 88 (1) , 108-109
A case of Acute Duodenal Diverticulitis with an Enterolith treated with endoscopic therapy
- 1 January 2016
- Published by Japan Gastrointestinal Endoscopy Society in Progress of Digestive Endoscopy
- Vol. 88 (1) , 108-109
A case of Acute Duodenal Diverticulitis with an Enterolith treated with endoscopic therapy
- 1 June 2015
- Published by Elsevier in Pancreatology
- Vol. 15 (3) , S112
High intensity focused ultrasound (HIFU) therapy for pancreatic cancer
- 1 June 2015
- Published by Elsevier in Pancreatology
- Vol. 15 (3) , S112
High intensity focused ultrasound (HIFU) therapy for pancreatic cancer
- 1 March 2015
- p. 557-60
[Current algorithm for the management of gallbladder cancer].
- Open Access
- 11 February 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 74
Case study to assess the safety of irreversible electroporation near the heart
Irreversible electroporation (IRE) is a promising technique for the focal treatment of soft tissue tumors. Even though the local application of an excessive electric field is a potential cause of cardiac arrhythmias, initial clinical studies have shown that IRE is generally safe when cardiac gating is employed. In this case report, we observed an episode of ventricular extrasystoles without hemodynamic changes during which time the synchronization device failed to operate properly, with pulses delivered not in the absolute refractory period but in the relative refractory period. At present, persons performing IRE must keep in mind that there is a small but real risk of synchronization failure even when a cardiac synchronization device is used. It is advisable to err on the side of caution when treating lesions near the heart.
- 11 February 2015
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 74
Open AccessCase study to assess the safety of irreversible electroporation near the heart
Irreversible electroporation (IRE) is a promising technique for the focal treatment of soft tissue tumors. Even though the local application of an excessive electric field is a potential cause of cardiac arrhythmias, initial clinical studies have shown that IRE is generally safe when cardiac gating is employed. In this case report, we observed an episode of ventricular extrasystoles without hemodynamic changes during which time the synchronization device failed to operate properly, with pulses delivered not in the absolute refractory period but in the relative refractory period. At present, persons performing IRE must keep in mind that there is a small but real risk of synchronization failure even when a cardiac synchronization device is used. It is advisable to err on the side of caution when treating lesions near the heart.
- 10 January 2015
- Published by Springer Nature in Journal of Medical Ultrasonics
- Vol. 42 (3) , 349-355
Value of shear wave elastography for predicting hepatocellular carcinoma and esophagogastric varices in patients with chronic liver disease
To assess the value of shear wave elastography (SWE) for predicting the presence of hepatocellular carcinoma (HCC) and esophagogastric varices (EGV) in patients with chronic liver disease. Liver tissue stiffness, as well as various other parameters potentially associated with HCC and portal hypertension, was measured by SWE in 273 patients with chronic liver disease. Among these patients, HCC was present in 89 and absent in 184, and EGV were present in 16 and absent in 257. The diagnostic performance of liver tissue stiffness and other clinical parameters in predicting the presence of HCC and EGV was evaluated using receiver operating characteristic (ROC) curves and the area under the ROC curve (AUROC). With regard to HCC, liver tissue stiffness was significantly higher in patients with HCC (18.65 ± 10.78 kPa) than in those without HCC (10.64 ± 8.04 kPa; P < 0.0001). Significant differences in patient age (P < 0.0001), albumin (P < 0.0001), platelet count (P < 0.0001), AFP (P < 0.0001), and DCP (P < 0.0001) were also observed between patients with and without HCC. Liver tissue stiffness showed the largest AUROC (0.791). With regard to EGV, liver tissue stiffness was significantly higher in patients with EGV (22.65 ± 10.19 kPa) than in those without EGV (12.67 ± 9.45 kPa; P < 0.0001). Significant differences in albumin (P < 0.0001) and platelet count (P < 0.0001) were also observed between patients with and without EGV. Liver tissue stiffness measured by SWE is an independent factor for predicting the presence of HCC and EGV in patients with chronic liver disease.
- 10 January 2015
- Published by Springer Nature in Journal of Medical Ultrasonics
- Vol. 42 (3) , 349-355
Value of shear wave elastography for predicting hepatocellular carcinoma and esophagogastric varices in patients with chronic liver disease
To assess the value of shear wave elastography (SWE) for predicting the presence of hepatocellular carcinoma (HCC) and esophagogastric varices (EGV) in patients with chronic liver disease. Liver tissue stiffness, as well as various other parameters potentially associated with HCC and portal hypertension, was measured by SWE in 273 patients with chronic liver disease. Among these patients, HCC was present in 89 and absent in 184, and EGV were present in 16 and absent in 257. The diagnostic performance of liver tissue stiffness and other clinical parameters in predicting the presence of HCC and EGV was evaluated using receiver operating characteristic (ROC) curves and the area under the ROC curve (AUROC). With regard to HCC, liver tissue stiffness was significantly higher in patients with HCC (18.65 ± 10.78 kPa) than in those without HCC (10.64 ± 8.04 kPa; P < 0.0001). Significant differences in patient age (P < 0.0001), albumin (P < 0.0001), platelet count (P < 0.0001), AFP (P < 0.0001), and DCP (P < 0.0001) were also observed between patients with and without HCC. Liver tissue stiffness showed the largest AUROC (0.791). With regard to EGV, liver tissue stiffness was significantly higher in patients with EGV (22.65 ± 10.19 kPa) than in those without EGV (12.67 ± 9.45 kPa; P < 0.0001). Significant differences in albumin (P < 0.0001) and platelet count (P < 0.0001) were also observed between patients with and without EGV. Liver tissue stiffness measured by SWE is an independent factor for predicting the presence of HCC and EGV in patients with chronic liver disease.